Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5097]
In development
Reference number: GID-TA11214
Expected publication date: TBC
As you will be aware, the Department for Health & Social Care has asked NICE to carry out a Single Technology Appraisal of Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation[ID5097].
Following on from advice received from the company, timelines for this appraisal are to be confirmed whilst the company confirm their regulatory filing plans.
As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.